Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $1,901,080.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $475.27, for a total value of $1,901,080.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $61,785.10. This trade represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

United Therapeutics Price Performance

NASDAQ UTHR opened at $489.31 on Monday. The company has a market cap of $21.07 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 4.86 and a beta of 0.86. The stock’s 50 day simple moving average is $452.91 and its 200-day simple moving average is $368.72. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $492.62.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the previous year, the business earned $6.39 earnings per share. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on UTHR. Bank of America increased their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Oppenheimer raised their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Wells Fargo & Company boosted their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a report on Monday, December 1st. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Clearstead Advisors LLC lifted its holdings in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 23 shares during the last quarter. Bessemer Group Inc. raised its position in United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 28 shares during the period. Archer Investment Corp raised its position in United Therapeutics by 9.5% in the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 31 shares during the period. F m Investments LLC lifted its stake in shares of United Therapeutics by 1.3% in the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after purchasing an additional 33 shares during the last quarter. Finally, HB Wealth Management LLC grew its holdings in shares of United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.